Search Results - "Bex, A."

Adjuvant sunitinib in renal cell carcinoma: from evidence to recommendation by Bex, A.

Get full text

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Rioux-Leclercq, N, Bex, A, Khoo, V, Grünwald, V, Gillessen, S, Horwich, A

Get full text

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Rioux-Leclercq, N, Bex, A, Khoo, V, Gruenvald, V, Horwich, A

Get full text

ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma by Powles, T., Albiges, L., Bex, A., Grünwald, V., Porta, C., Procopio, G., Schmidinger, M., Suárez, C., de Velasco, G.

“…•This special article provides key recommendations on the immunotherapy treatments of renal cell carcinoma.•Recommendations are based on available scientific…”
Get full text

Therapeutic ultrasound: The future of epilepsy surgery? by Bex, A., Bex, V., Carpentier, A., Mathon, B.

“…Epilepsy is one of the leading neurological diseases in both adults and children and in spite of advancement in medical treatment, 20 to 30% of patients remain…”
Get full text

Cryoablation and immunotherapy: an overview of evidence on its synergy by Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., Gómez, F. M.

“…Cancer cells can escape the immune system by different mechanisms. The evasion of cancer cells from immune surveillance is prevented by immune checkpoint…”
Get full text

Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Powles, T, Albiges, L, Bex, A, Comperat, E, Grünwald, V, Kanesvaran, R, Kitamura, H, McKay, R, Porta, C, Procopio, G, Schmidinger, M, Suarez, C, Teoh, J, de Velasco, G, Young, M, Gillessen, S

Get more information

Percutaneous Microwave Ablation of Histologically Proven T1 Renal Cell Carcinoma by Aarts, B. M., Prevoo, W., Meier, M. A. J., Bex, A., Beets-Tan, R. G. H., Klompenhouwer, E. G., Gómez, F. M.

“…Objectives To assess the safety and efficacy of percutaneous microwave ablation (MWA) of histologically proven T1 renal cell carcinoma (RCC). Methods We…”
Get full text

7 Adjuvant and neoadjuvant treatment in renal cell carcinoma (RCC) by Bex, A

Get full text

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer by Powles, T., Kayani, I., Blank, C., Chowdhury, S., Horenblas, S., Peters, J., Shamash, J., Sarwar, N., Boletti, K., Sadev, A., O'Brien, T., Berney, D., Beltran, L., Haanen, J., Bex, A.

“…The safety and efficacy of upfront sunitinib, before nephrectomy in metastatic clear cell renal cancer (mCRC), has not been prospectively evaluated. Two…”
Get full text

Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy by Hew, M N, Baseskioglu, B, Barwari, K, Axwijk, P H, Can, C, Horenblas, S, Bex, A, Rosette, J J M C H de la, Pes, M P Laguna

“…We validated the PADUA classification and assessed the R.E.N.A.L. nephrometry score to predict perioperative complications of partial nephrectomy. In addition,…”
Get more information

Cytoreductive nephrectomy in metastatic renal cell carcinoma: outcome of patients treated with a multidisciplinary, algorithm-driven approach by Liu, Wing K., Lam, J. M., Butters, T., Grant, M., Jackson-Spence, F., Bex, A., Powles, T., Szabados, B.

“…Purpose Metastatic renal cell carcinoma (mRCC) represents a significant and rising burden of disease, with rapidly evolving treatment modalities. The role of…”
Get full text

A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer by Powles, T., Kayani, I., Sharpe, K., Lim, L., Peters, J., Stewart, G.D., Berney, D., Sahdev, A., Chowdhury, S., Boleti, E., Shamash, J., Reynolds, A.R., Jones, R., Blank, C., Haanen, J., Bex, A.

“…Vascular endothelial growth factor (VEGF)-targeted therapy is administered continuously until progression in metastatic clear cell renal cancer (mRCC). The…”
Get full text

Interactive virtual 3D models of renal cancer patient anatomies alter partial nephrectomy surgical planning decisions and increase surgeon confidence compared to volume-rendered images by Hyde, E. R., Berger, L. U., Ramachandran, N., Hughes-Hallett, A., Pavithran, N. P., Tran, M. G. B., Ourselin, S., Bex, A., Mumtaz, F. H.

“…Purpose To determine whether the interactive visualisation of patient-specific virtual 3D models of the renal anatomy influences the pre-operative…”
Get full text

Sunitinib and other targeted therapies for renal cell carcinoma by Powles, T, Chowdhury, S, Jones, R, Mantle, M, Nathan, P, Bex, A, Lim, L, Hutson, T

“…Targeted therapy has radically altered the way metastatic renal cancer is treated. Six drugs are now licensed in this setting, with several other agents under…”
Get full text

A phase III, randomized, placebo-controlled trial of adjuvant nivolumab plus ipilimumab in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after radical or partial nephrectomy (CheckMate 914) by Bex, A., Grünwald, V., Russo, P., Tomita, Y., Berghorn, E., McHenry, M.B., Motzer, R.J.

Get full text

Cryoablation for the Treatment of Residual or Recurrent Disease After Prior Microwave Ablation of Renal Cell Carcinoma by Aarts, B. M., Baetens, T. R., Munoz, D. Corominas, Oudkerk, S. F., Solouki, A. M., Horsch, A. D., Bex, A., Beets-Tan, R. G. H., Klompenhouwer, E. G., Gómez, F. M.

Get full text

Variation in the management of cT1 renal cancer by surgical hospital volume: A nationwide study by Yildirim, H., Schuurman, M. S., Widdershoven, C. V., Lagerveld, B. W., Brink, L., Ruiter, A. E. C., Beerlage, H. P., Moorselaar, R. J. A., Graafland, N. M., Bex, A., Aben, K. K. H., Zondervan, P. J.

“…Objectives To analyse variation in clinical management of cT1 renal cell carcinoma (RCC) in the Netherlands related to surgical hospital volume (HV). Materials…”
Get full text

Prediction of early (30-day) and late (30–90-day) mortality after radical cystectomy in a comprehensive cancer centre over two decades by Korbee, M. L., Voskuilen, C. S., Hendricksen, K., Mayr, R., Wit, E. M., van Leeuwen, P. J., Horenblas, S., Meinhardt, W., Burger, M., Bex, A., van der Poel, H. G., van Rhijn, B. W. G.

“…Background Radical cystectomy (RC) is associated with substantial postoperative mortality. In this study, we analyzed early (30-day; 30 M) and late (30–90-day;…”
Get full text

Symptomatic brain metastases from small-cell carcinoma of the urinary bladder: The Netherlands Cancer Institute experience and literature review by Bex, A., Sonke, G.S., Pos, F.J., Brandsma, D., Kerst, J.M., Horenblas, S.

“…The incidence of symptomatic brain metastases in small-cell carcinoma of the urinary bladder (SCBC) is unknown. This precludes advice about prophylactic…”
Get full text